Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)

Trial Profile

Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Arimoclomol (Primary)
  • Indications Inclusion body myositis
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Apr 2017 Planned initiation date changed from 1 Apr 2017 to 1 May 2017.
    • 05 Feb 2017 Planned initiation date changed from 1 Jan 2017 to 1 Apr 2017.
    • 26 Sep 2016 Planned primary completion date changed from 1 Sep 2020 to 1 Dec 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top